The Mediator Drug Scandal: A Case of Corporate and Regulatory Failure

On March 29, 2021, a court in France issued a conviction against the pharmaceutical companies Servier Laboratories and the former director of operations, Jean-Philippe Seta, including the charge of unintentional homicide, for concealing the side effects of the drug Benfluorex for many years. The drug was closely linked to the risk of heart disease and high blood pressure, and it had been consumed by more than 5 million people before it was withdrawn from the market in late 2009.

The case became one of the most significant pharmaceutical scandals in France. A total of 12 individuals and 11 legal entities were tried, along with nine subsidiaries of the French National Agency for the Safety of Medicines and Health Products, for their role in a scandal that contributed to widespread mistrust in the pharmaceutical industry. The court proceedings were massive in scale, involving nearly 400 lawyers and thousands of claimants, with hearings spread across five rooms in a French court.

It is believed that around 500 people died as a result of this drug, although some experts stated that the true number may have been as high as 2,100. These figures intensified the public and legal significance of the case, especially given the long period during which the drug remained on the market despite the risks associated with it.

A few days ago, the appeal proceedings in the Mediator case were announced. Benfluorex had been sold under the trade name Mediator. The public prosecutor submitted 692 documents to the court, while more than 7,500 plaintiffs took part in the proceedings, including the French health insurance fund. The original trial court ruling itself exceeded 2,900 pages.

As a result of the initial judgment, fines of up to 2.7 million euros were issued, and Jean-Philippe Seta was sentenced to four years in prison with a suspended sentence, in addition to fines of up to 100,000 euros. At the same time, the court acquitted him of two charges: fraud and improperly obtaining marketing authorization.

The legal complications did not end there. The defendants’ lawyer requested an appeal of the verdict, which means that all victims and those who had already received financial compensation may now be required to return the amounts paid to them. Meanwhile, the public prosecutor and the victims challenged the acquittal of Jean-Philippe Seta on the two charges from which he had been cleared. The case is expected to continue until June 26 of this year.

It is also worth noting that the French National Agency for the Safety of Medicines and Health Products, the national health watchdog, was itself convicted for failing to suspend the marketing of Mediator immediately. The agency was fined 303,000 euros for its role in the scandal, and it did not appeal this ruling.

As for the drug itself, Benfluorex was authorized in 1976 for the treatment of high cholesterol in people with overweight or obesity and type 2 diabetes. It was also used as an appetite suppressant, which contributed to its broad use before its risks became fully exposed.